<DOC>
	<DOCNO>NCT00819338</DOCNO>
	<brief_summary>The principal purpose study determine whether increased intake n-3 polyunsaturated ( omega-3 ) fatty acid reduce amount fat store liver patient non-alcoholic fatty liver disease .</brief_summary>
	<brief_title>The Effect n-3 Polyunsaturated Fatty Acid Supplements Patients With Non-alcoholic Fatty Liver Disease</brief_title>
	<detailed_description>Non-alcoholic fatty liver disease ( NAFLD ) present 10-24 % general adult population . The first step NAFLD involve accumulation fat within liver ( steatosis ) . Steatosis occur either due defective generation , metabolism excretion fatty acid liver . The next step NAFLD progression inflammation , commonly occur due pro-inflammatory stimulus . Persistent inflammation result end-stage liver disease . NAFLD associate metabolic syndrome , characterised central obesity , insulin resistance , raise triglyceride hypertension . With current obesity epidemic , predict great number patient NAFLD future . Polyunsaturated fatty acid ( PUFAs ) essential component diet , though standard Western intake lower recommend amount . Supplementing long chain n-3 PUFAs ( commonly term omega-3 ) , EPA DHA , improve many metabolic syndrome feature . They low plasma triglyceride , may improve insulin resistance . The diet NAFLD patient tend deficient n-3 PUFAs excessive intake harmful n-6 PUFAs . This pattern mirror liver lipid content assess biopsy . Currently prove treatment NAFLD . Animal study limit study patient supportive benefit n-3 polyunsaturated fatty acid . This need assess .</detailed_description>
	<mesh_term>Liver Diseases</mesh_term>
	<mesh_term>Fatty Liver</mesh_term>
	<mesh_term>Non-alcoholic Fatty Liver Disease</mesh_term>
	<criteria>1 . Age great 18 year 2 . Liver biopsy diagnosis NAFLD 1 . Excessive alcohol intake &gt; 21 unit per week men &gt; 14 woman 2 . A liver disease diagnosis 3 . Poorly control diabetes HbA1c &gt; 8.0 % , use insulin sensitiser 4 . Pregnancy 5 . Cirrhosis 6 . Contraindications MR scan pacemaker metallic foreign body etc . 7 . Changes dose initiation lipid alter medication within precede three month , statin , fibrates systemic steroid 8 . Use n3 PUFA supplement within prior 4 month , adequate washout period 9 . Significant comorbid inflammatory illness determine research team</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2012</verification_date>
	<keyword>Non-alcoholic fatty liver disease</keyword>
	<keyword>Polyunsaturated fatty acid</keyword>
	<keyword>Omega-3</keyword>
</DOC>